Pharmacy Managers Unleash Big Data
30 June 2016
OptumRx was doing a routine analysis of a client’s prescription-drug claims when it noticed something odd. The company’s spending on acne medicine seemed high compared with those of other customers. Digging into the usage data for clues, the pharmacy arm of the health insurer, UnitedHealth Group, found that employees had been prescribed newer brand-name acne drugs that were, for the most part, combinations of older generic medicines. OptumRx began requiring patients to begin treatment with the cheaper remedies and switch to the pricier ones only if the others proved ineffective. Within six months, the 60,000-employee company had saved more than $70,000, OptumRx says.
ReVision Optics Receives FDA Approval for the Raindrop® Near Vision Inlay
29 June 2016
ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces receipt of U.S. Food and Drug Administration (FDA) approval for the Raindrop® Near Vision Inlay, a novel corneal inlay for the surgical correction of presbyopia. The Raindrop Near Vision Inlay is indicated to improve near vision by reshaping the anterior curvature of the cornea in presbyopic patients who have emmetropic refractions (+1.00 D to -0.50 D).
Diabetes Breakthrough Nears With Medtronic’s Artificial Pancreas
29 June 2016
The discovery of insulin almost a century ago was one of the most remarkable achievements in medical history, transforming a deadly disease into a manageable one. Now diabetics are on the cusp of another breakthrough, one that could ease the endless task of manually testing and adjusting their blood sugar levels.
Reality check from Eric Lander: Majority of cancer cures will take decades
29 June 2016
Softening the current optimism about curing cancer, a leading figure in genetics and disease research says it’ll take decades to transform the majority of cancers into chronic diseases instead of lethal ones.
FDA breaks up international scam putting bogus FDA labels on drugs
29 June 2016
The FDA has put another operator out of business that was falsely selling foreign-made drugs as if they were FDA-approved, but this one put a new twist on the practice. He bought drugs manufactured in India and elsewhere, doctored them to appear as if they were made in the U.S. and FDA-approved, then sold them to unsuspecting clients in other countries instead of the U.S.
China's biopharma boom at tipping point for growth, WuXi's Li says
29 June 2016
Explosive growth for China's biopharma industry spurred by the return of talent after high-profile stints at companies and universities in the U.S. will accelerate in the coming two decades, the chief of the country's top CRO tells Bloomberg.
28 June 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced top-line data from a Phase 2 exploratory, investigator-sponsored study to evaluate the safety, tolerability and efficacy of ganaxolone for the treatment of anxiety and attention in children with Fragile X Syndrome (FXS). The investigator selected Clinical Global Impression of Improvement (CGI-I), which is a broad scale to assess the overall improvement across the entire Fragile X Syndrome, as the primary endpoint of the study.
GlobalData on the difficulties and opportunities of Brexit for pharma
28 June 2016
While the exit of the UK from the EU undoubtedly creates significant issues for the UK pharmaceutical industry in ensuring highly regulated European markets remain open to business, opportunities remain for the sector to thrive, according to research and consulting firm GlobalData.
Reactions to the EU Referendum
28 June 2016
Steve Bates, Chief Executive of the UK BioIndustry Association (BIA), commented on the news: “This is not the outcome that the BIA wanted but we accept the views of the UK people. The life sciences sector is a resilient community, unfazed by new challenges and staffed by great management teams used to working in a global environment. The fundamentals of UK bioscience remain strong. In terms of potential new therapies in the pipeline, the UK is by far the strongest in Europe. But several key issues for our sector are now in flux.”
Japan biotech sector to benefit from delay in consumption tax hike
28 June 2016
Biopharmaceutical companies look to benefit, at least in the short term, after Japan's Prime Minister Shinzo Abe put off a planned 2 percent consumption tax hike scheduled for 2017. The increase now will not be introduced until at least October 2019. For biopharma companies, the move is likely to eliminate some uncertainty going forward.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024